Hereditary nephritis
MONDO:0005334A group of inherited conditions characterized initially by hematuria and slowly progressing to renal insufficiency. The most common form is the Alport syndrome (hereditary nephritis with hearing loss) which is caused by mutations in genes for type IV collagen and defective glomerular basement membrane.
Also known as: hereditary nephritis, familial nephritis, nephritis, familial
154 clinical trials for this condition and its sub-types, 17 tagged with Hereditary nephritis itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Hereditary nephritis
-
IgA glomerulonephritis 123 trials
-
Alport syndrome 17 trials · 18 incl. sub-types
5 sub-types
- X-linked Alport syndrome 3 trials
- Autosomal recessive Alport syndrome 2 trials
- Alport syndrome 3b, autosomal recessive 0 trials
- Autosomal dominant Alport syndrome 0 trials
- Digenic Alport syndrome 0 trials
-
C3 glomerulonephritis 7 trials
-
Karyomegalic interstitial nephritis 2 trials
-
Balkan nephropathy 1 trial
-
Complement factor H deficiency 0 trials
1 sub-type
-
New drug aims to slow kidney failure in rare genetic disease
Disease control OngoingThis study tests an experimental drug called BAY 3401016 in 60 adults aged 18 to 45 with Alport syndrome, a rare genetic condition that damages kidneys, hearing, and eyes. The drug works by blocking a protein thought to cause kidney injury, with the goal of slowing the loss of ki…
Phase 2 • Sponsor: Bayer • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New drug aims to plug kidney leaks in multiple diseases
Disease control OngoingThis phase 2 study tests the drug atrasentan in 103 adults with various kidney diseases that cause protein leakage, including IgA nephropathy and FSGS. Participants take a daily tablet to see if it reduces protein in urine, a sign of kidney damage. The goal is to find a new way t…
Phase 2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Newborn screening study aims to catch rare diseases at birth
Diagnosis OngoingThis study offers voluntary screening for newborns in North Carolina to detect a wide range of rare health conditions early. Using a small blood sample already collected at birth, the program tests for dozens of disorders, including spinal muscular atrophy, cystic fibrosis, and m…
Sponsor: RTI International • Aim: Diagnosis
Last updated Jul 03, 2026 00:00 UTC